# SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection

Clinical trial · Shenzhen Geno-Immune Medical Institute

- Archive id: nct:NCT03217617
- Published: 2017-07-14
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT03217617
- Source URL: https://clinicaltrials.gov/study/NCT03217617
- Provenance: clinicaltrials

## Abstract

This is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intravenous lentiviral gene transfer protocol.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: NOT_YET_RECRUITING
- phase: PHASE1, PHASE2
- study type: INTERVENTIONAL
- enrollment: 10
- sponsor: Shenzhen Geno-Immune Medical Institute
- conditions: SCID, X-Linked
- interventions: BIOLOGICAL: Direct intravenous injection of ivlv-X1 lentiviral vector
- start date: 2027-06-30
- start date type: ESTIMATED
- primary completion date: 2028-12-31
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Gene & Cell Therapy](https://space-kitty.com/topics/gene-cell-therapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.